These highlights do not include all the information needed to use CAMCEVI ETM

Manufacturer
Foresee Pharmaceuticals Co., Ltd. | Fareva Pau
Effective date
2025-08-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
daily-update
Hydrated at
2026-11-03 06:14:57

Label at a glance#

ProductCAMCEVI ETM
Active ingredientLEUPROLIDE MESYLATE
Label structure17 sections

Indications and uses

CAMCEVI ETM is indicated for the treatment of adult patients with advanced prostate cancer.

Dosage and administration

The recommended dose of CAMCEVI ETM is 21 mg administered subcutaneously once every 3 months. In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of metastatic castration-resistant prostate cancer. CAMCEVI ETM must be administered by a healthcare provider. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to...

Storage and handling

CAMCEVI ETM is a sterile, off-white to pale yellow, viscous, and opalescent injectable emulsion supplied in a kit as a single-dose, pre-filled syringe. CAMCEVI ETM is available as follows: Kit Contents NDC Injectable emulsion in a pre-filled syringe containing 21 mg leuprolide for subcutaneous injection, a sterile 18-gauge SurGuard ® 3 safety needle, and Prescribing Information. XXXXX-XXX-XX Store CAMCEVI ETM at 2...

Label contents#

Full prescribing information#

1. INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

CAMCEVI ETM is indicated for the treatment of adult patients with advanced prostate cancer.

2. DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.2 Preparation and Administration

DOSAGE & ADMINISTRATION SECTION

CAMCEVI ETM must be administered by a healthcare provider.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Important: Read the instructions completely before you administer CAMCEVI ETM for the first time. Do NOT substitute any of the components from the kit for administration.

CAMCEVI ETM is packaged in a blister in the kit. Check to make sure the kit contains:

  • One sterile, single-dose pre-filled syringe with plunger rod and backstop
  • One sterile 18-gauge SurGuard®3 safety needle, 5/8-inch needle
  • Prescribing Information

Follow the detailed instructions to ensure correct preparation of CAMCEVI ETM prior to administration:

STEP 1
Remove CAMCEVI ETM kit from refrigerator.
Keep the contents in their original, sealed blister carton and allow to sit at room temperature for 30 minutes before use.
Return to refrigerator after 30 minutes if not used.

image1image1image2image2

STEP 2
On a clean, dry surface, open carton and remove the contents. Examine all contents of the package. Do not use if any component is damaged.
Check the expiration date on the syringe. Do not use if the expiration date has passed.
The use of gloves is recommended during syringe assembly and administration.

image3image3

STEP 3
Remove pre-filled syringe (A) from the blister tray and open the safety needle (B) package by peeling back the paper tab.
The safety needle (B) package is located beneath the blister tray.
Visually inspect the syringe for particular matter prior to administration. The emulsion should appear off-white to pale yellow, viscous, and opalescent. Do not use if particulate matter is observed prior to administration.

image4image4

STEP 4
Remove the gray cap from the syringe (A).
Attach the needle (B) to the end of the syringe (A) by gently screwing clockwise with approximately a three-quarter turn until the needle is secure. Do not overtighten, as the needle hub may become damaged resulting in leakage of the product during injection. The safety sheath may also be damaged if the needle is overtightened onto the syringe.
See figure of assembled pre-filled syringe below.

image5image5
image6image6

STEP 5
Choose an injection site on the upper- or mid-abdominal area with sufficient soft or loose subcutaneous tissue that has not recently been used.
Clean the injection site with an alcohol swab.
Do NOT inject in areas with brawny or fibrous subcutaneous tissue or locations that can be rubbed or compressed (i.e., with a belt or clothing waistband). In addition, avoid applying heat directly to the site of CAMCEVI ETM injection.

image7image7

STEP 6
(1) Move the safety sheath away from the needle and towards the syringe and (2) remove the clear needle cover immediately before injection.
Note: Should the needle hub appear to be damaged, or leak, the product should NOT be used. The damaged needle should NOT be replaced and the product should NOT be injected. In the event of damage to the needle hub, use a new replacement CAMCEVI ETM kit.

image8image8

STEP 7
Use standard aseptic technique when performing the injection.
Grab and bunch the skin around the injection site with one hand.
Insert the needle at a 90° angle to the skin surface, and then release the bunched skin.

STEP 8
Inject the full contents of the syringe with a slow and steady push on the plunger, and then withdraw the needle at the same 90° angle used for insertion.

image descriptionimage description

STEP 9
Immediately following the withdrawal of the needle, activate the safety sheath using a finger/thumb or flat surface and push until it completely covers the needle tip and locks into place.
An audible and tactile “click” verifies a locked position.
Check to confirm the safety sheath is fully engaged.

STEP 10
After use, discard all components safely in a suitable sharps container. Dispose of the syringe and contaminated products according to local regulations/procedures.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Injectable emulsion: 21 mg leuprolide (equivalent to approximately 24 mg leuprolide mesylate) as a sterile, off-white to pale yellow, viscous, and opalescent emulsion in a single-dose, pre-filled syringe for subcutaneous injection.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

CAMCEVI ETM is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs, or any of the excipients in CAMCEVI ETM. Anaphylactic reactions to GnRH agonist analogs have been reported in medical literature.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Tumor Flare

WARNINGS AND PRECAUTIONS SECTION

CAMCEVI ETM, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment, declining thereafter to baseline levels or below by the end of the second week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of CAMCEVI ETM treatment. Patients treated with CAMCEVI ETM may experience a temporary increase in bone pain, which can be managed symptomatically.

Cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.

Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

5.2 Hyperglycemia and Diabetes

WARNINGS AND PRECAUTIONS SECTION

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent the development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.

5.3 Cardiovascular Diseases

WARNINGS AND PRECAUTIONS SECTION

Increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.

5.4 QT/QTc Prolongation

WARNINGS AND PRECAUTIONS SECTION

Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

5.5 Convulsions

WARNINGS AND PRECAUTIONS SECTION

Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI ETM [see Adverse Reactions (6.2)]. Manage patients receiving a GnRH agonist who experience convulsions according to current clinical practice.

5.6 Severe Cutaneous Adverse Reactions

SPL UNCLASSIFIED SECTION

CAMCEVI ETM can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). SCARs, including SJS/TEN, DRESS, and AGEP, occurred in patients receiving CAMCEVI ETM or other GnRH agonists; including cases with visceral involvement and/or requiring skin grafts [see Adverse Reactions (6.2)].

Monitor patients for the development of SCARs.

If a SCAR is suspected, interrupt CAMCEVI ETM until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other Grade 4 skin reactions, permanently discontinue CAMCEVI ETM.

5.7 Laboratory Tests

WARNINGS AND PRECAUTIONS SECTION

Monitor serum levels of testosterone following injection of CAMCEVI ETM. In the majority of patients treated with CAMCEVI ETM, testosterone levels increased above baseline during the first week, and then declined thereafter to castration levels (<50 ng/dL) within 4 weeks [see Clinical Studies (14) and Adverse Reactions (6)].

5.8 Embryo-Fetal Toxicity

SPL UNCLASSIFIED SECTION

Based on findings in animal studies and mechanism of action, CAMCEVI ETM can cause fetal harm when administered to a pregnant woman. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus [see Use in Specific Population (8.1), Clinical Pharmacology (12.1)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions are discussed in greater detail in other sections of the labeling:

6.1 Clinical Trial Experience

CLINICAL TRIALS EXPERIENCE SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CAMCEVI ETM was evaluated in an open-label, single arm, clinical trial (FP01C-17-001), patients with advanced prostate cancer received CAMCEVI ETM administered subcutaneously at a dose of 21 mg on Day 0 and Day 84 [see Clinical Studies (14)]. Of 144 patients enrolled, 132 (92%) received both doses of CAMCEVI ETM.

Serious adverse reactions occurred in 6% of patients who received CAMCEVI ETM. Serious adverse reactions included acute myocardial infarction, cerebrovascular accident, drug induced liver injury, and pancreatitis (each 0.7%).

Permanent discontinuation of CAMCEVI ETM due to an adverse reaction occurred in 0.7% of patients (stroke).

The most common (≥5%) adverse reactions, including laboratory abnormalities, were increased triglycerides, increased alanine aminotransferase, hot flush, hypertension, decreased hemoglobin, increased sodium, increased aspartate aminotransferase, injection site reaction, weight increase, increased potassium, decreased neutrophils, and decreased white blood cells.

Table 1 summarizes the most common (≥5%) adverse reactions in FP01C-17-001.

Table 1. Adverse Reactions Occurring in ≥5% of Patients - FP01C-17-001
a Only includes a grade 3 adverse reaction. Hypertension includes blood pressure increased, essential hypertension, and hypertension.
b Injection site reaction includes injection site erythema, hemorrhage, induration, nodule, localized edema; and injection site pain.

Adverse Reaction

All Grades

N = 144

(%)

Grade 3-4a
N = 144
(%)

Hot flush

24

0

Hypertensiona

15

0.7

Injection site reactionb

10

0

Weight increase

8

0

Clinically relevant adverse reactions in < 5% of patients who received CAMCEVI ETM included insomnia, acute myocardial infarction, cerebrovascular accident, diabetes mellitus, decreased libido, and electrocardiogram QT prolonged.

Table 2 summarizes laboratory abnormalities in FP01C-17-001.

Table 2. Laboratory Abnormalities Occurring in ≥5% of Patients - FP01C-17-001
a Only includes a grade 3 adverse reaction.

Laboratory Abnormality

All Grades
N = 144
(%)

Grade 3-4 a
N = 144
(%)

Chemistry

Increased triglycerides

44

1.4

Increased alanine aminotransferase

28

0.7

Increased sodium

13

0

Increased aspartate aminotransferase

13

0

Increased potassium

7

0

Hematology

Decreased hemoglobin

15

0

Decreased neutrophils

6

0

Decreased white blood cells

6

0

6.2 Postmarketing Experience

POSTMARKETING EXPERIENCE SECTION

The following adverse reactions have been identified during post approval use of leuprolide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse reactions were reported.

Allergic Conditions: anaphylactoid or asthmatic process, rash, urticaria, and photosensitivity reactions
Cardiovascular System: hypotension, myocardial infarction, pulmonary embolism
Central/Peripheral Nervous System: convulsion, peripheral neuropathy, spinal fracture/paralysis
Endocrine System: pituitary apoplexy, diabetes
Hepato-biliary disorder: drug-induced liver injury
Hematologic: white blood cells decreased
Psychiatric: mood swings, including depression, suicidal ideation and attempt
Respiratory, thoracic and mediastinal disorder: interstitial lung disease
Musculoskeletal System: decreased bone density, tenosynovitis-like symptoms, fibromyalgia
Skin and Subcutaneous: injection site reactions, SJS/TEN, DRESS, AGEP, dermatitis exfoliative, bullous dermatitis, and erythema multiforme
Urogenital System: prostate pain

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

Based on findings in animal studies and mechanism of action, CAMCEVI ETM can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose (see data). Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.

Data

Animal Data

Major fetal malformations were observed in developmental and reproductive toxicology studies in rabbits after a single administration of a monthly formulation of leuprolide administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (approximately 1/1500 to 1/15 the human dose based on body surface area using an estimated daily dose in animals and humans). Since a depot formulation was utilized in the study, a sustained exposure to leuprolide was expected throughout the period of organogenesis and to the end of gestation. Similar studies in rats did not demonstrate an increase in fetal malformations, however, there was increased fetal mortality and decreased fetal weights with the two higher doses of the monthly formulation of leuprolide in rabbits and with the highest dose in rats.

8.2 Lactation

LACTATION SECTION

Risk Summary

The safety and efficacy of CAMCEVI ETM have not been established in females. There is no information regarding the presence of leuprolide in human milk, the effects on the breast-fed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

8.3 Females and Males of Reproductive Potential

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION

Infertility

Males

Based on findings in animals and mechanism of action, CAMCEVI ETM may impair fertility in males of reproductive potential [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and efficacy of CAMCEVI ETM in pediatric patients have not been established.

8.5 Geriatric Use

GERIATRIC USE SECTION

Of the 144 patients who received CAMCEVI ETM in the FP01C-17-001, 74% were 65 years of age or older, while 31% were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients over the age of 65 and younger patients.

11 DESCRIPTION

DESCRIPTION SECTION

CAMCEVI ETM is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI ETM is designed to deliver approximately 21 mg of leuprolide over 3 months.

Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide mesylate (salt) with the following structural formula. The pH of 50 mg/mL solution of leuprolide mesylate in water is approximately 5.7.

image10
image10

CAMCEVI ETM is supplied as a kit with a pre-filled, single-dose, sterile syringe for subcutaneous injection. Each pre-filled syringe delivers 21 mg leuprolide (equivalent to approximately 24 mg leuprolide mesylate), poly (D, L-lactide-co-Glycolide) (160 mg) polymer and N-methyl-2-pyrrolidone (116 mg).

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Leuprolide, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Mean serum testosterone concentrations transiently increased, then fell to below castrate threshold levels (< 50 ng/dL) within 4 weeks following administration of the dose of leuprolide, and generally remained below castrate thresholds levels throughout treatment.

In humans, subcutaneous administration of single daily doses of leuprolide result in an initial increase in circulating levels of LH and FSH, leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males). However, continuous daily administration of leuprolide results in decreased levels of LH and FSH. In males, testosterone is reduced to below castration levels. These decreases generally occur within 2 to 4 weeks after initiation of treatment, and castration levels of testosterone in prostatic cancer patients have been demonstrated for periods of up to 5 years.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Leuprolide concentration is variable, exhibiting an initial rapid increase followed by a rapid decline over the first 3 days before reaching steady concentrations for the duration of the dosing interval. The mean serum leuprolide Cmax was 34.8 ng/mL following the first dose and 32.6 ng/mL following the second dose of CAMCEVI ETM. The mean serum leuprolide concentration was maintained at 0.32 – 1.91 ng/mL after Day 3 following the first dose and maintained at 0.23 – 2.02 ng/mL after Day 3 following the second dose. The mean AUC0-3 mon was 80.1 day.ng/mL following the first dose and 92.9 day.ng/mL following the second dose of CAMCEVI ETM.

Absorption

The median Tmax of leuprolide was 4 hours following the first and second doses of CAMCEVI ETM.

Distribution

The mean steady-state volume of distribution of leuprolide was 27 L following an intravenous bolus in healthy male volunteers. Protein binding of leuprolide ranged from 43% to 49% in vitro.

Elimination

The mean systemic clearance was 7.6 L/h and terminal elimination half-life of approximately 3 hours following an intravenous bolus of leuprolide in healthy male volunteers.

Metabolism

Administration of radiolabeled leuprolide was metabolized to smaller inactive peptides which may then be further catabolized.

Excretion

Excretion of leuprolide has not been evaluated with CAMCEVI ETM.

Specific Populations

No clinically significant differences in the systemic exposure of leuprolide were observed based on age (51 to 89 years), race (White, Asian), or body weight (54 to 119 kg). The effect of renal or hepatic impairment on the pharmacokinetics of leuprolide has not been evaluated.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Two-year carcinogenicity studies were conducted with leuprolide in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice, no pituitary abnormalities were observed at a dose as high as 60 mg/kg for 2 years. Patients have been treated with leuprolide for up to 3 years with doses as high as 10 mg/day and for 2 years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.

Mutagenicity studies have been performed with leuprolide using bacterial and mammalian systems. These studies provided no evidence of mutagenic potential.

Leuprolide may reduce male and female fertility. Administration of leuprolide to male and female rats at doses of 0.024, 0.24, and 2.4 mg/kg as monthly depot formulation for up to 3 months (approximately as low as 1/30 of the human dose based on body surface area using an estimated daily dose in animals and humans) caused atrophy of the reproductive organs, and suppression of reproductive function. These changes were reversible upon cessation of treatment.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

The efficacy of CAMCEVI ETM was evaluated in an open label, single arm, multinational study FP01C-17-001 (NCT03261999) in patients with advanced prostate carcinoma who have a screening morning serum testosterone level >150 ng/dL and Eastern Cooperative Oncology Group performance status ≤ 2. CAMCEVI ETM was administered subcutaneously at a dose of 21 mg initially on Day 0 and on Week 12.

The population (n = 144) had a median age of 70 years (range 51 to 89) and was 88% White, 11% Asian, and 1% Black. Disease stage was distributed as follows: 5% metastatic (M1), 41% locally advanced (T3/4 NX M0 or any T N1 M0), 30% localized (T1 or T2 N0 M0), and 24% not classifiable.

The major efficacy outcome measure was medical castration rate, defined as achieving and maintaining serum testosterone suppression to < 50 ng/dL by Week 4 through Week 24 of treatment. Following the first injection of CAMCEVI ETM, serum testosterone levels were suppressed to < 50 ng/dL by Week 4 (+/-1day) in 97.9% of the patients; and from Week 4 through Week 24 in 97.2% of patients (95% CI: 92.7- 98.9) estimated using the Kaplan-Meier method. The time course of change from baseline in testosterone suppression are shown in Figure 1. The percentage of patients with testosterone suppression to < 20 ng/dL was 70.8% on Day 28.

Figure 1 CAMCEVI ETM Mean (95% CI) Percentage Change from Baseline in Serum Testosterone Concentration Over Time

image11
image11

Note: 1 subject with baseline testosterone value < 0.05 ng/mL was excluded from analysis.

In the clinical trial, PSA levels were monitored and were lowered on average by 48% after 4 weeks after administration of CAMCEVI ETM, 88% after 3 months and remained suppressed throughout the 24 weeks of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline correlates with clinical benefit.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

CAMCEVI ETM is a sterile, off-white to pale yellow, viscous, and opalescent injectable emulsion supplied in a kit as a single-dose, pre-filled syringe. CAMCEVI ETM is available as follows:

Kit Contents

NDC

Injectable emulsion in a pre-filled syringe containing 21 mg leuprolide for subcutaneous injection, a sterile 18-gauge SurGuard®3 safety needle, and Prescribing Information.

XXXXX-XXX-XX

Store CAMCEVI ETM at 2°C to 8°C (36°F to 46°F). Protect CAMCEVI ETM from light by storing in the original package until time of use. Do not freeze or shake.

Excursions permitted to room temperature 25°C (77°F) for up to 6 days.

The rubber used in syringe tip cap and plunger stopper is not made of natural rubber latex.

17  PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Hypersensitivity

  • Inform patients that if they have experienced hypersensitivity with other GnRH agonist drugs like CAMCEVI ETM, CAMCEVI ETM is contraindicated [see Contraindications (4)].

Tumor Flare

  • Inform patients that CAMCEVI ETM can cause tumor flare during the first weeks of treatment. Inform patients that the increase in testosterone can cause an increase in urinary symptoms or pain. Advise patients to contact their healthcare provider if uretral obstruction, spinal cord compression, paralysis, or new or worsened symptoms occur after beginning CAMCEVI ETM treatment [see Warnings and Precautions (5.1)].

Hyperglycemia and Diabetes

  • Advise patients that there is an increased risk of hyperglycemia and diabetes with CAMCEVI ETM therapy. Inform patients that periodic monitoring for hyperglycemia and diabetes is required when being treated with CAMCEVI ETM [see Warnings and Precautions (5.2)].

Cardiovascular Diseases

  • Inform patients that there is an increased risk of myocardial infarction, sudden cardiac death, and stroke with CAMCEVI ETM treatment. Advise patients to immediately report signs and symptoms associated with these events to their healthcare provider for evaluation [see Warnings and Precautions (5.3)].

QT/QTc Prolongation

  • Inform patients that CAMCEVI ETM can cause QT/QTc prolongation. Advise patients to immediately contact their healthcare provider in the event of syncope, presyncopal symptoms, or cardiac palpitations [see Warnings and Precautions (5.4) ].

Convulsions

  • Inform patients that there is an increased risk of convulsions with CAMCEVI ETM treatment. Advise patients to immediately contact their healthcare provider if they experience convulsions [see Warnings and Precautions (5.5)].

Severe Cutaneous Adverse Reactions

  • Inform patients that severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which may be life threatening or fatal, may occur during treatment with CAMCEVI ETM. Advise patients to contact their healthcare provider or seek medical attention right away if they experience signs or symptoms of SCARs, e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy [see Warnings and Precautions (5.6)].

Injection Site Reactions

  • Inform patients that injection site related adverse reactions may occur such as transient burning/stinging, pain, bruising, and redness. Advise patients to contact their healthcare provider if they experience rash or severe injection site reactions [see Adverse Reactions (6.1)].

Urogenital Disorders

  • Advise patients that CAMCEVI ETM may cause impotence.

Infertility

Manufactured for:
Foresee Pharmaceuticals Co., Ltd.
Taipei City 115, Taiwan (R.O.C.)


By:
Fareva Pau
Fareva Pau, Avenue du Bearn, IDRON, 64320, France

PRINCIPAL DISPLAY PANEL -Blister Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

blister
blister

PRINCIPAL DISPLAY PANEL -Carton Label (front)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

carton-label (front)
carton-label (front)

PRINCIPAL DISPLAY PANEL -Carton Label (back)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

carton-label (back)
carton-label (back)

PRINCIPAL DISPLAY PANEL -Syringe Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

syringe
syringe

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72851-10072851-100-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N219745-001CAMCEVI ETMLEUPROLIDE MESYLATEEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25

Orange Book patents#

Current patent rows page 1 of 1 · 5 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N219745-001106465722027-01-16Drug product2026-06-03
N219745-00197442072027-01-16Drug product2026-06-03
N219745-00195728572029-08-02Drug product2026-06-03
N219745-001121338782037-12-18Drug product2026-06-03
N219745-001117175552039-01-01Drug product2026-06-03

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 1 matching rows.

Application-product, Exclusivity code, Expiration table
Application-productExclusivity codeExpiration
N219745-001NS2028-08-25

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25d4dbc9d85df4…
2026-10-15 13:18:302026-09N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25c2088c7a36db…
2026-09-14 22:38:342026-08N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-2584e616aacf4f…
2026-08-18 06:07:402026-07N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-2531067a03dcf5…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-001CAMCEVI ETMEQ 21MG BASEEMULSION / SUBCUTANEOUSRLD, RS2025-08-25a50c72e98297…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N219745-001106465722027-01-16Drug product2026-06-03d4dbc9d85df4…
2026-11-14 07:37:172026-10N219745-00197442072027-01-16Drug product2026-06-03d4dbc9d85df4…
2026-11-14 07:37:172026-10N219745-00195728572029-08-02Drug product2026-06-03d4dbc9d85df4…
2026-11-14 07:37:172026-10N219745-001121338782037-12-18Drug product2026-06-03d4dbc9d85df4…
2026-11-14 07:37:172026-10N219745-001117175552039-01-01Drug product2026-06-03d4dbc9d85df4…
2026-10-15 13:18:302026-09N219745-001106465722027-01-16Drug product2026-06-03c2088c7a36db…
2026-10-15 13:18:302026-09N219745-00197442072027-01-16Drug product2026-06-03c2088c7a36db…
2026-10-15 13:18:302026-09N219745-00195728572029-08-02Drug product2026-06-03c2088c7a36db…
2026-10-15 13:18:302026-09N219745-001121338782037-12-18Drug product2026-06-03c2088c7a36db…
2026-10-15 13:18:302026-09N219745-001117175552039-01-01Drug product2026-06-03c2088c7a36db…
2026-09-14 22:38:342026-08N219745-001106465722027-01-16Drug product2026-06-0384e616aacf4f…
2026-09-14 22:38:342026-08N219745-00197442072027-01-16Drug product2026-06-0384e616aacf4f…
2026-09-14 22:38:342026-08N219745-00195728572029-08-02Drug product2026-06-0384e616aacf4f…
2026-09-14 22:38:342026-08N219745-001121338782037-12-18Drug product2026-06-0384e616aacf4f…
2026-09-14 22:38:342026-08N219745-001117175552039-01-01Drug product2026-06-0384e616aacf4f…
2026-08-18 06:07:402026-07N219745-001106465722027-01-16Drug product2026-06-03caaa826d4ba7…
2026-08-18 06:07:402026-07N219745-00197442072027-01-16Drug product2026-06-03caaa826d4ba7…
2026-08-18 06:07:402026-07N219745-00195728572029-08-02Drug product2026-06-03caaa826d4ba7…
2026-08-18 06:07:402026-07N219745-001121338782037-12-18Drug product2026-06-03caaa826d4ba7…
2026-08-18 06:07:402026-07N219745-001117175552039-01-01Drug product2026-06-03caaa826d4ba7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-001106465722027-01-16Drug product2026-06-03a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-00197442072027-01-16Drug product2026-06-03a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-00195728572029-08-02Drug product2026-06-03a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-001121338782037-12-18Drug product2026-06-03a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-001117175552039-01-01Drug product2026-06-03a50c72e98297…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2026-11-14 07:37:172026-10N219745-001NS2028-08-25d4dbc9d85df4…
2026-10-15 13:18:302026-09N219745-001NS2028-08-25c2088c7a36db…
2026-09-14 22:38:342026-08N219745-001NS2028-08-2584e616aacf4f…
2026-08-18 06:07:402026-07N219745-001NS2028-08-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219745-001NS2028-08-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219745-001NS2028-08-2531067a03dcf5…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219745-001NS2028-08-25a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CAMCEVI ETMLEUPROLIDEForesee Pharmaceuticals Co., Ltd.5fc04a39-4024-4d95-a32c-b8ea6cd6f2232025-08-08Warnings, Adverse reactionsExact identifier
ndc (package): 72851-100-01
ndc (product): 72851-100
ndc11 (package): 72851010001
spl id: 14ea9819-02e5-446c-95c0-1b6133521112
spl set id: 5fc04a39-4024-4d95-a32c-b8ea6cd6f223

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.